Venture Life Group (LON:VLG) Reaches New 1-Year High - Still a Buy?

Key Points

• Venture Life Group plc reached a new 52-week high of GBX 63 ($0.83) during trading, with the last trade at GBX 61.25 ($0.81) on a volume of 739,734 shares.
• The company reported quarterly earnings of GBX 3.96 ($0.05) EPS and maintains a debt-to-equity ratio of 28.45 with a market cap of £78.05 million.
• Insider Jerry Randall purchased 50,000 shares at an average price of GBX 59 ($0.78), indicating confidence in the stock, which has 10.41% insider ownership.

Venture Life Group plc (LON:VLG - Get Free Report)'s stock price hit a new 52-week high during mid-day trading on Friday . The company traded as high as GBX 63 ($0.84) and last traded at GBX 61.25 ($0.81), with a volume of 739734 shares traded. The stock had previously closed at GBX 60 ($0.80).

Venture Life Group Price Performance

The company has a debt-to-equity ratio of 28.45, a current ratio of 2.22 and a quick ratio of 1.48. The company has a market capitalization of £82.19 million, a PE ratio of 109.46, a price-to-earnings-growth ratio of 5.67 and a beta of 0.30. The stock's 50 day simple moving average is GBX 55 and its 200-day simple moving average is GBX 45.69.

Venture Life Group (LON:VLG - Get Free Report) last issued its quarterly earnings results on Monday, June 30th. The company reported GBX 3.96 ($0.05) earnings per share (EPS) for the quarter. Venture Life Group had a net margin of 1.44% and a return on equity of 0.99%. As a group, equities analysts forecast that Venture Life Group plc will post 6.1391542 earnings per share for the current fiscal year.

Insider Transactions at Venture Life Group

In other Venture Life Group news, insider Jerry Randall purchased 50,000 shares of the business's stock in a transaction on Wednesday, July 2nd. The shares were bought at an average cost of GBX 59 ($0.78) per share, for a total transaction of £29,500 ($39,207.87). 10.41% of the stock is owned by company insiders.

Venture Life Group Company Profile

Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the global self-care market. With operations in the UK, The Netherlands and Italy, the Group's product portfolio includes some key products such as the UltraDEX and Dentyl oral care product ranges, food supplements for maintaining brain function, medical devices for women's intimate healthcare, fungal infections and proctology, and dermo-cosmetics for addressing the signs of ageing. The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies and grocery multiples.